Replies to post #8024 on GTC Biotherapeutics (fka GTCB)

[kris_kade]

Atryn potential use in antithrombin deficiency in patients undergoing coronary artery bypass surgeries which is potentially a $150 million to $200 million-a-year market, might draw a partner soon to the table plus for other indications such as burns..

Remember, Dr. Cox comments says 'multiple parties' :-)